Sponsored

ImpediMed Limited (ASX:IPD) & NSW Health Partnership Update: Lymphoedema Prevention Program Expanded

  • November 17, 2020 02:33 PM AEDT
  • Kunal Sawhney
    Kunal Sawhney
    CEO Kunal Sawhney
    2781 Posts

    Kunal Sawhney is founder & CEO at Kalkine and is a richly experienced and accomplished financial professional with a wealth of knowledge in the Australian Equities Market. Kunal obtained a Master of Business Administration degree from University of T...

ImpediMed Limited (ASX:IPD) & NSW Health Partnership Update: Lymphoedema Prevention Program Expanded

Summary

  • New South Wales (NSW) Health is additionally expanding patient access to the Lymphoedema Prevention Program (Program), notified ImpediMed Limited (ASX:IPD).
  • This uses the SOZO® Digital Health Platform and involves the purchase of 25 additional SOZO® units.
  • SOZO® is the most advanced, noninvasive bioimpedance spectroscopy (BIS) device that delivers a precise snapshot of tissue composition and fluid status in less than 30 seconds.
  • It uses ImpediMed’s BIS technology to measure 256 unique data points over a broad spectrum of frequencies from 3 kHz to 1000 kHz.
  • NSW Health is one of the largest providers of the SOZO® Digital Health Platform in Australia, with over 45 units purchased to date.
  • The Program utilises ImpediMed's Test, Trigger, Treat™ protocol to perceive and intercede in cancer-related lymphoedema.

“Program expansion with existing customers is a critical aspect of our growth strategy in the coming quarters”, says Richard Carreon, Managing Director and CEO of ImpediMed Limited.

In a significant partnership update with NSW Health, ImpediMed notified that NSW Health is further expanding patient access to its Lymphoedema Prevention Program using the SOZO® Digital Health Platform through the purchase of 25 additional SOZO® units.

This ASX market update seemed to have garnered investors’ interest.  Post soaring by over 3% to $ 0.096 yesterday, IPD shares traded 14.6% up to $0.110 during early trade hours on 17 November.

ImpediMed Limited (ASX:IPD) is a medical technology company that uses bioimpedance spectroscopy (BIS) technology to create powerful data to maximise patient health.

ImpediMed & NSW Health Partnership Expansion

In April 2020, ImpediMed announced the purchase of eight additional SOZO® units. Five such devices were deployed in NSW Health’s Western NSW Local Health District. Post the successful implementation of the Lymphoedema Prevention Program, NSW Health is likely to use the new devices to further expand patient access in metropolitan as well as rural areas.

Notably, at present, NSW Health is one of the largest providers of the SOZO® Digital Health Platform in Australia, with more than 45 units purchased to date.

READ ABOUT IMPEDIMED & ASTRAZENECA’S SECOND CONTRACT HERE

Acquainting with NSW Health

NSW Health is committed to offering access to lymphoedema prevention programs to as many patients as possible and seem to be an impeccable partner to ImpediMed.

The Lymphoedema Prevention Program

The key aim of the Program is to educate healthcare providers and patients that with the proper protocols in place, lymphoedema can be detected as well as managed before becoming a debilitating chronic condition.

The Program utilises ImpediMed's Test, Trigger, Treat™ protocol for prompt discovery and intervention of cancer-linked lymphoedema. Routine lymphoedema testing of cancer fighters makes use of  ImpediMed’s SOZO® device with BIS (LDex®) technology.

A noteworthy upsurge in a patient's L-Dex score is a trigger to assess the patient and initiate intervention. ImpediMed's PREVENT Trial is the biggest multi-site, randomised controlled trial that has been ever performed to study lymphoedema prevention, according to the Company. So much so, the protocol resulted in a 95% reduction in lymphoedema progression at one year.

SOZO® Digital Health Platform

SOZO® is an FDA-cleared, CE-marked and ARTG-listed digital health platform. It delivers an accurate snapshot of fluid status as well as tissue composition in under 30 seconds. It measures 256 unique data points over a widespread spectrum of frequencies that range from 3 kHz to 1000 kHz. Results are immediately available online, facilitating easy data access and sharing across an entire healthcare system.

SOZO® supports early detection of secondary lymphoedema. It also provides fluid status for patients living with heart failure. Besides, it can be used to monitor and maintain overall health- entirely on a single device.

 

 


Disclaimer
The website https://kalkinemedia.com/au is a service of Kalkine Media Pty. Ltd. (Kalkine Media) A.C.N. 629 651 672. The principal purpose of the content on this website is to provide factual information only and does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stock of the company (or companies) or engage in any investment activity under discussion. We are neither licensed nor qualified to provide investment advice through this platform. In providing you with the content on this website, we have not considered your objectives, financial situation or needs. You should make your own enquiries and obtain your own independent advice prior to making any financial decisions.
Some of the images that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed on this website unless stated otherwise. The images that may be used on this website are taken from various sources on the web and are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it below the image. The information provided on the website is in good faith, however Kalkine Media does not make any representation or warranty regarding the content, accuracy, or use of the content on the website.

 

   
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK